1. Asher, M. I., Montefort, S., Bjorksten, B., Lai, C. K., Strachan, D. P., Weiland, S. K., Williams, H., & ISAAC Phase Three Study Group. (2006). Worldwide time trends in the prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and eczema in childhood: ISAAC phases one and three repeat multicountry cross-sectional surveys. The Lancet, 368, 733–743.
2. Bacsi, A., Dharajiya, N., Choudhury, B. K., & Boldogh, I. (2005). Effect of pollen-mediated oxidative stress on immediate hypersensitivity reactions and late-phase inflammation in allergic conjunctivitis. The Journal of Allergy and Clinical Immunology, 116, 836–843.
3. Bacsi, A., Choudhury, B. K., Dharajiya, N., Sur, S., & Boldogh, I. (2006). Subpollen particles: Carriers of allergenic proteins and oxidases. The Journal of Allergy and Clinical Immunology, 118, 844–850.
4. Behrendt, H., & Becker, W. M. (2001). Localization, release and bioavailability of pollen allergens: The influence of environmental factors. Current Opinion in Immunology, 13, 709–715.
5. Besancenot, J.-P., Thibaudon, M., & Cecchi, L. (2011). Has allergenic pollen an impact on non-allergic diseases? European Annals of Allergy Clinical Immunology, 43(3), 69–76.